Blog
RSS FeedPosted by Michael Wonder on 26 Sep 2023
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
26 September 2023 - NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for ...
Posted by Michael Wonder on 24 Sep 2023
NICE recommends Lilly's mirikizumab (Omvoh) for the treatment of eligible adults with moderately to severely active ulcerative colitis
22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately ...
Posted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 14 Sep 2023
First treatment for acute migraine to be recommended by NICE set to benefit thousands
14 September 2023 - The first treatment to be recommended by NICE for treating acute migraine will soon be available on ...
Posted by Michael Wonder on 12 Sep 2023
NICE issues two recommendations for UCB's inflammatory disease drug
11 September 2023 - NICE has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now ...
Posted by Michael Wonder on 12 Sep 2023
Taking a proportionate approach to technology appraisals
12 September 2023 - In 2022, NICE introduced the first phase of a new proportionate approach to technology appraisals. ...
Posted by Michael Wonder on 08 Sep 2023
NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes
8 September 2023 - Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment ...
Posted by Michael Wonder on 06 Sep 2023
Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy
6 September 2023 - NICE has published final evidence-based recommendations on the use of mavacamten (Camzyos) for the treatment of ...
Posted by Michael Wonder on 05 Sep 2023
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
4 September 2023 - NICE has recommended Chiesi’s Elfabrio (pegunigalsidase alfa) as a long-term option for treating Fabry disease in ...
Posted by Michael Wonder on 01 Sep 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis
1 September 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Aug 2023
Dupilumab for the treatment of patients with prurigo nodularis
23 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 18 Aug 2023
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
18 August 2023 - Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder ...
Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of ...
Posted by Michael Wonder on 15 Aug 2023
Cipaglucosidase alfa and miglustat for the treatment of patients with late-onset Pompe disease
15 August 2023 - NICE has published evidence-based recommendations on the use of cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for ...
Posted by Michael Wonder on 07 Aug 2023
GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran
1 August 2023 - Local GP leaders across the south of England have told practices not to follow the NHS’s ...